一个代谢合成的致死性酸酸3-酶驱动的癌症
Guillaume P Andrieu1,2, Mathieu Simonin3,4,5, Aurélie Cabannes-Hamy6
1Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker Enfants-Malades, Université Paris Cité, Paris, France. guillaume.andrieu@inserm.fr.
Nature communications
|March 4, 2025
概括
针对PI3K驱动的癌症,如T-ALL,包括阻断mTOR和谷氨胺代谢. 这种双重方法利用代谢漏洞来有效治疗癌症.
科学领域:
- 在瘤学瘤学.
- 癌症新陈代谢 癌症新陈代谢
- 分子生物学分子生物学
背景情况:
- 氨基酸3-激酶 (PI3K) 途径的放松调节在侵袭性癌症中很常见,从而赋予代谢可塑性和治疗耐药性.
- 由PI3K驱动的瘤,特别是T细胞急性淋巴细胞白血病 (T-ALL),具有独特的代谢脆弱性,但仍未得到充分的向.
- 了解PI3K改变的癌症中的代谢适应对于开发新的治疗策略至关重要.
研究的目的:
- 调查与T-ALL.中的PI3K信号改变相关的代谢负债.
- 在PI3K驱动的癌症中识别和利用谷氨酸溶解和糖溶解之间的代谢交叉.
- 开发一种新的治疗策略,针对PI3K改变的恶性瘤中的代谢脆弱性.
主要方法:
- 在PI3K改变的T-ALL模型中探索代谢途径.
- 制药抑制了拉巴胺素 (mTOR) 途径的机械性标.
- 在临床前和临床癌症模型中评估结合的谷氨胺降解和mTOR抑制.
主要成果:
- 确定了一种由PI3K信号驱动的代谢交叉链,将谷氨酸溶解和糖溶解联系起来.
- 经PI3K改变的细胞表现出可塑性,在mTOR抑制时利用谷氨作为挽救途径.
- 抑制谷氨胺降解和抑制mTOR的组合表明对PI3K驱动的固体和血液瘤有显著的细胞毒性.
结论:
- 针对谷氨酸溶解和糖溶解之间的代谢交叉是PI3K驱动癌症的可行策略.
- 结合抑制谷氨胺代谢和mTOR有效地克服了癌细胞的适应性抵抗.
- 这项研究提出了一种新的治疗方法,以规避代谢适应和向PI3K驱动的癌症.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Phosphoinositides and PIPs
7.7K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
7.7K


